Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 419 participants.
Also called NCT04857840
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 419 participants
- Sponsor
- Registry
-
NCT04857840
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada
- Registry status
- Terminated
Technical summary
Registry record NCT04857840. Randomized; double masking; primary purpose treatment. Start 2021-08-05 (actual); primary completion 2023-01-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)
- Acronym
- REFRESH
- Condition
- Hypertension (HTN)
- Intervention (Drug)
- Firibastat (QGC001) Period 1
- Lead sponsor
- Quantum Genomics SA
- Collaborator
- PRA Health Sciences
Record details
- Record id
cardio:ct-nct04857840- Content hash
57abacfc1a2e7c3e9dc9e9e4a1b72df6978b9acb49ca06c80be5891ce004d26f